GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (FRA:12X1) » Definitions » EBITDA Margin %

Anavex Life Sciences (FRA:12X1) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Anavex Life Sciences's EBITDA for the three months ended in Dec. 2023 was €-10.36 Mil. Anavex Life Sciences's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, Anavex Life Sciences's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Anavex Life Sciences EBITDA Margin % Historical Data

The historical data trend for Anavex Life Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences EBITDA Margin % Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anavex Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anavex Life Sciences's EBITDA Margin %

For the Biotechnology subindustry, Anavex Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's EBITDA Margin % falls into.



Anavex Life Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Anavex Life Sciences's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-43.602/0
= %

Anavex Life Sciences's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-10.356/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anavex Life Sciences  (FRA:12X1) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Anavex Life Sciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (FRA:12X1) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (FRA:12X1) Headlines

No Headlines